These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
191 related items for PubMed ID: 8334029
1. 24,25-dihydroxy vitamin D3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients. Mortensen BM, Aarseth HP, Ganss R, Haug E, Gautvik KM, Gordeladze JO. Bone; 1993; 14(2):125-31. PubMed ID: 8334029 [Abstract] [Full Text] [Related]
2. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. Mortensen BM, Gordeladze JO, Lyngdal PT, Aarseth HP, Gautvik KM. Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728 [Abstract] [Full Text] [Related]
9. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V, Torregrosa V. Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742 [Abstract] [Full Text] [Related]
13. Effect of PTH and 1,25(OH)2D3 on renal 25(OH)D3 metabolism, adenylate cyclase, and protein kinase. Armbrecht HJ, Wongsurawat N, Zenser TV, Davis BB. Am J Physiol; 1984 Jan; 246(1 Pt 1):E102-7. PubMed ID: 6320659 [Abstract] [Full Text] [Related]
14. In vivo regulation of chromogranin A messenger ribonucleic acid in the parathyroid by 1,25-dihydroxyvitamin D: studies in normal rats and in chronic renal insufficiency. Soliman E, Canaff L, Fox J, Hendy GN. Endocrinology; 1997 Jun; 138(6):2596-600. PubMed ID: 9165053 [Abstract] [Full Text] [Related]
15. Effect of 24,25(OH)2D3 on PTH levels and bone histology in dogs with chronic uremia. Olgaard K, Finco D, Schwartz J, Arbelaez M, Teitelbaum S, Avioli L, Klahr S, Slatopolsky E. Kidney Int; 1984 Dec; 26(6):791-7. PubMed ID: 6335904 [Abstract] [Full Text] [Related]
16. Oral administration of 24,25(OH)2D3 suppresses the serum parathyroid hormone levels of dialysis patients. Ben-Ezer D, Shany S, Conforty A, Rapoport J, Edelstein S, Bdolah-Abram T, Kafka DR, Chaimovitz C. Nephron; 1991 Dec; 58(3):283-7. PubMed ID: 1896092 [Abstract] [Full Text] [Related]
17. Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone. Birkenhäger-Frenkel DH, Pols HA, Zeelenberg J, Eijgelsheim JJ, Schot R, Nigg AL, Weimar W, Mulder PG, Birkenhäger JC. J Bone Miner Res; 1995 Feb; 10(2):197-204. PubMed ID: 7754799 [Abstract] [Full Text] [Related]
18. Modulation of parathyroid hormone-sensitive adenylate cyclase in ROS 17/2.8 cells by dexamethasone 1,25-dihydroxyvitamin D3 and protein kinase C. Rao LG, Wylie JN. Bone Miner; 1993 Oct; 23(1):35-47. PubMed ID: 8274878 [Abstract] [Full Text] [Related]
19. Differential effects of parathyroid hormone on the renal 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 production of young and adult rats. Armbrecht HJ, Wongsurawat N, Zenser TV, Davis BB. Endocrinology; 1982 Oct; 111(4):1339-44. PubMed ID: 6981502 [Abstract] [Full Text] [Related]
20. Effects of 1alpha,25-dihydroxy-16ene, 23yne-vitamin D3 on osteoblastic function in human osteosarcoma SaOS-2 cells: differentiation-stage dependence and modulation by 17-beta estradiol. Rao LG, Sutherland MK, Reddy GS, Siu-Caldera ML, Uskokovic MR, Murray TM. Bone; 1996 Dec; 19(6):621-7. PubMed ID: 8968029 [Abstract] [Full Text] [Related] Page: [Next] [New Search]